SC
CNTA

SummitTX Capital’s Centessa Pharmaceuticals CNTA Stock Holding History

SummitTX Capital’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.22M Sell
206,847
-125,861
-38% -$3.22M 0.26% 87
2025
Q4 		$8.32M Buy
+332,708
New +$8.43M 0.25% 97
2025
Q2 		– Sell
-28,381
Closed -$408K – 791
2025
Q1 		$408K Buy
+28,381
New +$464K 0.02% 593

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

SummitTX Capital's CNTA Position: Q1 2026 in Review

SummitTX Capital reduced its Centessa Pharmaceuticals (CNTA) stake by 38% in Q1 2026, selling an estimated $3.22M and leaving 206,847 shares worth $8.22M. The position accounts for 0.26% of the portfolio, ranked #87.

SummitTX Capital first reported a position in CNTA in Q1 2025 and has held it in 3 quarters since. The position peaked at $8.32M in Q4 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • SummitTX Capital held 206,847 shares of Centessa Pharmaceuticals worth $8.22M as of Q1 2026.
  • SummitTX Capital sold 125,861 Centessa Pharmaceuticals shares in Q1 2026, an estimated $3.22M.
  • Centessa Pharmaceuticals made up 0.26% of SummitTX Capital's portfolio in Q1 2026, its #87 holding.
  • SummitTX Capital first reported a position in Centessa Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • SummitTX Capital's Centessa Pharmaceuticals position peaked at $8.32M in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.